CL2012000182A1 - Tableta que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)pirimidinil]metil]-4-fluorobenzonitrilo en un 35 a 50% en peso y un fluidizador; y método para producirla. - Google Patents

Tableta que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)pirimidinil]metil]-4-fluorobenzonitrilo en un 35 a 50% en peso y un fluidizador; y método para producirla.

Info

Publication number
CL2012000182A1
CL2012000182A1 CL2012000182A CL2012000182A CL2012000182A1 CL 2012000182 A1 CL2012000182 A1 CL 2012000182A1 CL 2012000182 A CL2012000182 A CL 2012000182A CL 2012000182 A CL2012000182 A CL 2012000182A CL 2012000182 A1 CL2012000182 A1 CL 2012000182A1
Authority
CL
Chile
Prior art keywords
methyl
fluorobenzonitrile
fluidizer
dioxo
piperidinyl
Prior art date
Application number
CL2012000182A
Other languages
English (en)
Spanish (es)
Inventor
Yusuke Okabe Takayuki Murakawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2012000182A1 publication Critical patent/CL2012000182A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2012000182A 2009-07-28 2012-01-23 Tableta que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)pirimidinil]metil]-4-fluorobenzonitrilo en un 35 a 50% en peso y un fluidizador; y método para producirla. CL2012000182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009175695 2009-07-28

Publications (1)

Publication Number Publication Date
CL2012000182A1 true CL2012000182A1 (es) 2012-10-12

Family

ID=43529294

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000182A CL2012000182A1 (es) 2009-07-28 2012-01-23 Tableta que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)pirimidinil]metil]-4-fluorobenzonitrilo en un 35 a 50% en peso y un fluidizador; y método para producirla.

Country Status (23)

Country Link
US (1) US20120129878A1 (enEXAMPLES)
EP (1) EP2460523B1 (enEXAMPLES)
JP (1) JP5732394B2 (enEXAMPLES)
KR (1) KR20120039046A (enEXAMPLES)
CN (1) CN102548556A (enEXAMPLES)
AU (1) AU2010279171A1 (enEXAMPLES)
BR (1) BR112012001959A2 (enEXAMPLES)
CA (1) CA2769177A1 (enEXAMPLES)
CL (1) CL2012000182A1 (enEXAMPLES)
CO (1) CO6612226A2 (enEXAMPLES)
CR (1) CR20120061A (enEXAMPLES)
EA (1) EA201270204A1 (enEXAMPLES)
EC (1) ECSP12011699A (enEXAMPLES)
IL (1) IL217560A0 (enEXAMPLES)
IN (1) IN2012DN00954A (enEXAMPLES)
MA (1) MA33539B1 (enEXAMPLES)
MX (1) MX2012001284A (enEXAMPLES)
PE (1) PE20120919A1 (enEXAMPLES)
SG (1) SG178062A1 (enEXAMPLES)
TN (1) TN2012000031A1 (enEXAMPLES)
TW (1) TW201106991A (enEXAMPLES)
WO (1) WO2011013639A1 (enEXAMPLES)
ZA (1) ZA201200761B (enEXAMPLES)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
KR102145641B1 (ko) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 고형 제제
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN105078974A (zh) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及药物组合物
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN105596341B (zh) * 2016-03-14 2018-08-10 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
KR102408085B1 (ko) * 2016-05-10 2022-06-13 니폰 조키 세야쿠 가부시키가이샤 아세트아미노펜 제제의 제조 방법
CN114122219B (zh) * 2020-08-28 2025-04-08 群创光电股份有限公司 发光单元
CN116763752B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种阿卡波糖片剂及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP2711528B2 (ja) * 1995-12-20 1998-02-10 大洋薬品工業株式会社 ロキソプロフェン製剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
PL376733A1 (pl) 2002-11-01 2006-01-09 Takeda Pharmaceutical Company Limited Środek do zapobiegania lub leczenia neuropatii
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP4919252B2 (ja) * 2004-08-05 2012-04-18 株式会社明治 顆粒状製剤及びその製造方法
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
PE20070338A1 (es) 2005-08-10 2007-04-16 Takeda Pharmaceutical Derivados heterociclicos como agentes terapeuticos para diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
UA95296C2 (uk) 2006-06-27 2011-07-25 Такеда Фармасьютікал Компані Лімітед Конденсовані циклічні сполуки
CN103211819A (zh) 2006-09-13 2013-07-24 武田药品工业株式会社 2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
TWI460176B (zh) 2006-10-19 2014-11-11 Takeda Pharmaceutical 吲哚化合物
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
EA200970746A1 (ru) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
EP2120885A2 (en) * 2007-03-13 2009-11-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
US8400391B2 (en) 2008-01-10 2013-03-19 Honeywell International Inc. Method and system for improving dimming performance in a field sequential color display device

Also Published As

Publication number Publication date
JP5732394B2 (ja) 2015-06-10
CA2769177A1 (en) 2011-02-03
MA33539B1 (fr) 2012-08-01
EP2460523A1 (en) 2012-06-06
WO2011013639A1 (ja) 2011-02-03
US20120129878A1 (en) 2012-05-24
JPWO2011013639A1 (ja) 2013-01-07
TW201106991A (en) 2011-03-01
TN2012000031A1 (en) 2013-09-19
IL217560A0 (en) 2012-02-29
CN102548556A (zh) 2012-07-04
EA201270204A1 (ru) 2012-08-30
EP2460523A4 (en) 2014-02-26
KR20120039046A (ko) 2012-04-24
AU2010279171A1 (en) 2012-03-01
BR112012001959A2 (pt) 2016-03-15
CR20120061A (es) 2012-03-06
ZA201200761B (en) 2013-05-29
ECSP12011699A (es) 2012-03-30
CO6612226A2 (es) 2013-02-01
PE20120919A1 (es) 2012-08-13
EP2460523B1 (en) 2017-01-04
SG178062A1 (en) 2012-03-29
MX2012001284A (es) 2012-03-26
IN2012DN00954A (enEXAMPLES) 2015-04-10

Similar Documents

Publication Publication Date Title
CL2012000182A1 (es) Tableta que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)pirimidinil]metil]-4-fluorobenzonitrilo en un 35 a 50% en peso y un fluidizador; y método para producirla.
MX344084B (es) Procedimiento para la síntesis regioselectiva de derivados de ácido 1-alquil-3-haloalquil-pirazol-4-carboxílico.
SMT201500003B (it) Nuovo derivato di fenilimidazolo come inibitore dell'enzima PDE10A
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
PE20081734A1 (es) Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
HRP20180859T1 (hr) 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
PH12013502473A1 (en) Oil-or-fat-processed starch and method for producing the same
MX2009005829A (es) Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
SMT201400158B (it) Derivati eteroaromatici di fenilimidazolo come inibitori dell'enzima pde10a
PA8855501A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
UA111827C2 (uk) Спосіб отримання інгенол-3-ангелату
MX2010004570A (es) Metodos para la produccion de sal.
UY31883A (es) Nuevo procedimiento de síntesis de 7,8-dimetoxi-1, 3-dihidro-2h-3-benzazepin-2-ona, y aplicación en la síntesis de ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
CR20120261A (es) Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
UY32499A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
MY158910A (en) Surface modified silicic acid semi-gels
UA104420C2 (uk) Застосування похідних глутарової кислоти або їх фармацевтично прийнятних солей як протиаритмічних засобів
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
PH12015501146A1 (en) Hydantoin derivative
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A